Huntington disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat. Its length can be used to estimate the time of clinical diagnosis, which is defined by overt motor symptoms. Non-motor symptoms begin before motor onset, and involve changes in hypothalamus-regulated functions such as sleep, emotion and metabolism. Therefore we hypothesized that hypothalamic changes occur already prior to the clinical diagnosis. We performed voxel-based morphometry and logistic regression analyses of crosssectional MR images from 220 HD gene carriers and 75 controls in the Predict-HD study. We show that changes in the hypothalamic region are detectable before clinical diagnosis and that its grey matter contents alone are sufficient to distinguish HD gene carriers from control cases. In conclusion, our study shows, for the first time, that alterations in grey matter contents in the hypothalamic region occur at least a decade before clinical diagnosis in HD using MRI.
Introduction
Huntington disease (HD) is a fully penetrant hereditary neurodegenerative disorder caused by an expanded CAG repeat in the HD gene (HDCRG, 1993) . The length of the CAG repeat correlates negatively with the age of onset and can be used to estimate it (Langbehn et al. 2004) . The clinical diagnosis of HD is currently defined by the presence of overt motor disturbances (Philips et al., 2008) . Striatal atrophy is well established in clinical HD and has been linked to chorea, whereas changes in the cerebral cortex have been correlated with cognitive decline (Aylward et al., 2004; Kipps et al., 2005; 2007; Paulsen et al., 2006b; 2010; Wolf et al., 2007; Rosas et al., 2005; 2008) . However, circadian rhythm changes, sleep abnormalities, psychiatric complications, as well as increased appetite and metabolic alterations are common and often precede motor symptoms by many years (Trejo et al., 2004; Morton et al., 2005; Underwood et al., 2006; Mochel et al., 2007; Julien et al., 2007; van Duijn et al., 2007; Duff et al., 2007; Arnulf et al., 2008; Videnovic et al., 2009 ). These disturbed functions may be caused by changes in the hypothalamus and neuroendocrine circuitries (Petersén et al., 2009 ). In fact, recent studies have shown that hypothalamic atrophy is present in HD patients in early disease stages as well as in transgenic HD mice using voxel-based morphometry (VBM) of MR images (Kassubek et al., 2004; Douaud et al., 2006; Sawiak et al., 2009) . Furthermore, microglia activation and reductions in dopamine D2 receptor levels occur in the hypothalamic region even before onset of motor symptoms in HD gene carriers (Politis et al., 2008) . Finally orexin loss in the hypothalamus and alterations in the hypothalamic-pituitary-adrenal axis including increased levels of cortisol and insulin growth factor-1 have been shown in patients with HD from an early disease stage (Petersén et al., 2005; Björkqvist et al., 2006; Aziz et al., 2008; 2009; Saleh et al., 2009) .
Despite intense research during the last decade, there is still no cure or satisfactory treatment for this fatal disorder. Biomarkers that define disease states before clinical diagnosis are urgently needed in the development of potential therapeutic interventions. The Predict-HD study constitutes a multi-national effort to identify such early diseaserelated changes by longitudinally characterizing individuals carrying the HD gene but who have not yet reached the stage of clinical diagnosis (Paulsen et al., 2006a; 2008) . In light of the recent findings of 
